The authors concluded that NLR has higher sensitivity and specificity in distinguishing uterine sarcomas from leiomyomas, suggesting that alternative biomarkers may provide more useful information than CA125 alone. This evidence concerns the gene MUC16 and uterine corpus sarcoma.